|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment securities (includes available-for-sale securities with a fair value and an amortized cost basis of $1.5 billion and $1.6 billion in 2026, respectively, and $1.5 billion and $1.6 billion in 2025, respectively) | ||||||||||||||||||||
| Net finance receivables (includes loans of consolidated VIEs of $14.7 billion in 2026 and $13.4 billion in 2025) | ||||||||||||||||||||
| Unearned insurance premium and claim reserves | ||||||||||||||||||||
| Allowance for finance receivable losses (includes allowance of consolidated VIEs of $1.7 billion in 2026 and $1.6 billion in 2025) | ||||||||||||||||||||
| Net finance receivables, less unearned insurance premium and claim reserves and allowance for finance receivable losses | ||||||||||||||||||||
| Restricted cash and restricted cash equivalents (includes restricted cash and restricted cash equivalents of consolidated VIEs of $729 million in 2026 and $690 million in 2025) | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Long-term debt (includes debt of consolidated VIEs of $12.7 billion in 2026 and $11.5 billion in 2025) | ||||||||||||||||||||
| Insurance claims and policyholder liabilities | ||||||||||||||||||||
| Deferred and accrued taxes | ||||||||||||||||||||
| Other liabilities (includes other liabilities of consolidated VIEs of $32 million in 2026 and $30 million in 2025) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 2,000,000,000 shares authorized, 114,575,373 and 117,196,792 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost; 21,475,215 and 18,514,904 shares at September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...